
WHAT IS CLAIMED IS:

1. A compound of Formula (I):



(I),

or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, wherein:

G^1 and G^2 are each independently a bond, C_2-C_{12} alkylene, or C_2-C_{12} alkenylene, wherein one or more -CH_2- in the alkylene or alkenylene is optionally replaced by -O-;

L^1 is –OC(=O)R^1, -C(=O)OR^1, -OC(=O)OR^1, -C(=O)R^1, -OR^1, -S(O)$_x$$R^1$, -S-S$R^1$, -C(=O)S$R^1$, -SC(=O)$R^1$, -N$R^a$C(=O)$R^1$, -C(=O)N$R^b$$R^c$, -N$R^a$C(=O)N$R^b$$R^c$, -OC(=O)N$R^b$$R^c$, -N$R^a$C(=O)O$R^1$, -SC(=S)$R^1$, -C(=S)S$R^1$, -C(=S)$R^1$, -CH(OH)$R^1$, -P(=O)(O$R^b$)(O$R^c$), -($C_6$-$C_{10}$ arylene)-R^1, -(6- to 10-membered heteroarylene)-R^1, or R^1;

L^2 is –OC(=O)R^2, -C(=O)OR^2, -OC(=O)OR^2, -C(=O)R^2, -OR^2, -S(O)$_x$$R^2$, -S-S$R^2$, -C(=O)S$R^2$, -SC(=O)$R^2$, -N$R^d$C(=O)$R^2$, -C(=O)N$R^e$$R^f$, -N$R^d$C(=O)N$R^e$$R^f$, -OC(=O)N$R^e$$R^f$, -N$R^d$C(=O)O$R^2$, -SC(=S)$R^2$, -C(=S)S$R^2$, -C(=S)$R^2$, -CH(OH)$R^2$, -P(=O)(O$R^e$)(O$R^f$), -($C_6$-$C_{10}$ arylene)-R^2, -(6- to 10-membered heteroarylene)-R^2, or R^2;

R^1 and R^2 are each independently C_6-C_{32} alkyl or C_6-C_{32} alkenyl;

R^a, R^b, R^d, and R^e are each independently H, C_1-C_{24} alkyl, or C_2-C_{24} alkenyl;

R^c and R^f are each independently C_1-C_{32} alkyl or C_2-C_{32} alkenyl;

G^3 is C_2-C_{24} alkylene, C_2-C_{24} alkenylene, C_3-C_8 cycloalkylene, or C_3-C_8 cycloalkenylene;

R^3 is -N(R^4)R^5;

R^4 is C_3-C_8 cycloalkyl, C_3-C_8 cycloalkenyl, 4- to 8-membered heterocyclyl, or C_6-C_{10} aryl; ~~or R^4, G^3 or part of G^3, together with the nitrogen to which they are attached form a cyclic moiety~~and R^4 is unsubstituted or substituted with one or more hydroxyl, halogen, C_1-C_6 alkyl, or oxo;


R^5 is C_1-C_{12} alkyl or C_3-C_8 cycloalkyl; ~~or R^4,~~and R^5~~, together~~ is unsubstituted, substituted with ~~the nitrogen to which they are attached form a cyclic moiety~~one or more hydroxyl, or substituted with one or more hydroxyl and one or more oxo;

x is 0, 1 or 2; and——

wherein each alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, alkylene, alkenylene, cycloalkylene, cycloalkenylene, arylene, and heteroarylene~~, and cyclic moiety~~ is independently optionally substituted~~.~~,

wherein prodrug is acetate, formate and benzoate derivatives of alcohol or amide derivatives of amine functional groups of said compound of Formula (I).

2. A compound of Formula (II):



(II),

or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, wherein:

$\overline{\text{------}}$ is a single bond or a double bond;

G^1 and G^2 are each independently a bond, C_2-C_{12} alkylene, or C_2-C_{12} alkenylene, wherein one or more -CH_2- in the alkylene or alkenylene is optionally replaced by -O-;

L^1 is –OC(=O)R^1, -C(=O)OR^1, -OC(=O)OR^1, -C(=O)R^1, -OR^1, -S(O)$_x$$R^1$, -S-S$R^1$, -C(=O)S$R^1$, -SC(=O)$R^1$, -N$R^a$C(=O)$R^1$, -C(=O)N$R^b$$R^c$, -N$R^a$C(=O)N$R^b$$R^c$, -OC(=O)N$R^b$$R^c$, -N$R^a$C(=O)O$R^1$, -SC(=S)$R^1$, -C(=S)S$R^1$, -C(=S)$R^1$, -CH(OH)$R^1$, -P(=O)(O$R^b$)(O$R^c$), -($C_6$-$C_{10}$ arylene)-R^1, -(6- to 10-membered heteroarylene)-R^1, or R^1;

L^2 is –OC(=O)R^2, -C(=O)OR^2, -OC(=O)OR^2, -C(=O)R^2, -OR^2, -S(O)$_x$$R^2$, -S-S$R^2$, -C(=O)S$R^2$, -SC(=O)$R^2$, -N$R^d$C(=O)$R^2$, -C(=O)N$R^e$$R^f$, -N$R^d$C(=O)N$R^e$$R^f$, -OC(=O)N$R^e$$R^f$, -N$R^d$C(=O)O$R^2$, -SC(=S)$R^2$, -C(=S)S$R^2$, -C(=S)$R^2$, -CH(OH)$R^2$, -P(=O)(O$R^e$)(O$R^f$), -($C_6$-$C_{10}$ arylene)-R^2, -(6- to 10-membered heteroarylene)-R^2, or R^2;

R^1 and R^2 are each independently C_6-C_{32} alkyl or C_6-C_{32} alkenyl;

R^a, R^b, R^d, and R^e are each independently H, C_1-C_{24} alkyl, or C_2-C_{24} alkenyl;

R^c and R^f are each independently C_1-C_{32} alkyl or C_2-C_{32} alkenyl;

G^4 is a bond, C_1-C_{23} alkylene, C_2-C_{23} alkenylene, C_3-C_8 cycloalkylene, or C_3-C_8 cycloalkenylene;

R^3 is $-N(R^4)R^5$;

R^4 is C_1-C_{12} alkyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkenyl, 4- to 8-membered heterocyclyl, or C_6-C_{10} aryl; ~~or R^4, G^3 or part of G^3, together with the nitrogen to which they are attached form a cyclic moiety;~~

R^5 is C_1-C_{12} alkyl or C_3-C_8 cycloalkyl; or R^4, R^5, together with the nitrogen to which they are attached form a cyclic moiety;

x is 0, 1 or 2; and

wherein each alkyl, alkenyl, cycloalkyl, cycloalkenyl, heterocyclyl, aryl, alkylene, alkenylene, cycloalkylene, cycloalkenylene, arylene, heteroarylene, and cyclic moiety is independently optionally substituted.


3. The compound of claim ~~2,~~1, wherein ~~------~~G^1 and G^2 are each independently C_2-C_{12} alkylene, preferably is a ~~single bond.~~compound of Formula (I-A):

~~4. The compound of claim 2, wherein ------ is a double bond.~~

~~5. The compound of any one of claims 1 to 4, wherein G^1 and G^2 are each independently C_2-C_{12} alkylene.~~

~~6. The compound of claim 5, wherein G^1 and G^2 are each independently C_5 alkylene.~~

~~7. The compound of claim 5, which is a compound of Formula (I-A):~~




(I-A),

wherein y and z are each independently an integer from 2 to 12,

or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, more preferably G^1 and G^2 are each independently C_5 alkylene.

~~8.~~4. The compound of claim ~~5,~~2, which is a compound of Formula (II-A):



(II-A),


wherein y and z are each independently an integer from 2 to 12,

or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.


~~9. The compound of claim 7 or 8, wherein y is 5 and z is 5.~~

~~10.~~5. The compound of any one of claims 1 to ~~9,~~4, wherein L^1 is $-OC(=O)R^1$, $-C(=O)OR^1$, or $-C(=O)NR^bR^c$; and L^2 is $-OC(=O)R^2$, $-C(=O)OR^2$, or $-C(=O)NR^eR^f$.


~~11.~~6. The compound of claim 1, which is a compound of Formula (I-B), (I-B'), (I-B"), (I-C), (I-D), or (I-E):




(I-B),




(I-B'),




(I-B"),



(I-C),




(I-D), or




(I-E),


preferably is a compound of Formula (I-F), (I-F'), (I-F"), (I-G), (I-H), or (I-I):




(I-F),




(I-F'),




(I-F"),



(I-G),



(I-H), or




(I-I),

wherein y and z are each independently an integer from 2 to 12, more preferably wherein y is 5 and z is 5,


or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.

~~12.~~7. The compound of claim 2, which is a compound of Formula (II-B), (II-B'), (II-B"), (II-


C), (II-D), or (II-E):




(II-B),




(II-B'),




(II-B"),



(II-C),




(II-D), or




(II-E),

or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof~~.~~,


~~13. The compound of claim 11, which~~preferably is a compound of Formula (~~I~~II-F), (~~I~~II-F'), (~~I~~II-F"), (~~I~~II-G), (~~I~~II-H), or (~~I~~II-I):




(II ~~I~~-F),




(II ~~I~~-F'),




(II ~~I~~-F"),



(II ~~I~~-G),



(II ~~I~~-H), or





(II ~~I~~-I),

wherein y and z are each independently an integer from 2 to 12,

or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof~~.~~,


~~14. The compound of claim 12, which~~more preferably is a compound of Formula (II-~~F~~J), (II-~~F'~~J'), (II-~~F~~J"), (II-~~G~~K), (II-~~H~~L), or (II-~~I~~M):






(II-J'),


(II-J),




(II-K),



(II-J"),



(II-L), or



(II-M).

~~wherein y and z are each independently an integer from 2 to 12,~~

~~or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.~~


~~15. The compound of claim 13 or 14, wherein y is 5 and z is 5.~~

~~16.~~8. The compound of any one of claims 1 to-~~7~~15, wherein G^3 is C_2- C_4~~C~~$_{24}$ alkylene, wherein optionally G^3 is substituted with one or more oxo.


~~17. The compound of claim 16, wherein G^3 is C_2-C_4 alkylene.~~

~~18. The compound of claim 16 or 17, wherein G^3 is substituted with one or more oxo.~~


~~19.~~9. The compound of claim 1, which is a compound of Formula (I-J), (I-J'), (I-J"), (I-K), (I-L), or (I-M):




(I-J),




(I-J'),




(I-J"),



(I-K),



(I-L), or



(I-M),

wherein y and z are each independently an integer from 2 to 12, and

s is an integer from 2 to 24, preferably wherein y is 5, z is 5, and s is 2 or 4,

or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.

~~20. The compound of claim 19, wherein y is 5, z is 5, and s is 2.~~

~~21. The compound of claim 19, wherein y is 5, z is 5, and s is 4.~~

~~22. The compound of any one of claims 1 to 15, wherein G^4 is a bond.~~

~~23. The compound of any one of claims 1 to 15, wherein G^4 is C_1-C_{23} alkylene.~~

~~24. The compound of claim 2, which is a compound of Formula (II-J), (II-J'), (II-J"), (II-K), (II-L), or (II-M):~~

~~wherein y and z are each independently an integer from 2 to 12, and~~

~~u is an integer from 0 to 23,~~


~~or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.~~

~~25. The compound of claim 24, wherein y is 5, z is 5, and u is 0.~~


~~26. The compound of any one of claims 1 to 25, wherein R^5 is unsubstituted.~~

~~27. The compound of any one of claims 1 to 25, wherein R^5 is substituted with one or more hydroxyl.~~


~~28.~~10. The compound of claim 1, which is a compound of Formula (I-N), (I-N'), (I-N"), (I-O), (I-P), or (I-Q):




(I-N),




(I-N'),




(I-N"),



(I-O),



(I-P), or



(I-Q),

wherein y and z are each independently an integer from 2 to 12,


s is an integer from 2 to 24,

t is an integer from 1 to 12, and


R^6 is hydrogen or hydroxyl,

or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.


~~13.~~11. The compound of claim 2, which is a compound of Formula (II-N), (II-N'), (II-N"), (II-O), (II-P), or (II-Q):




(II-N),




(II-N'),






(II-N"),



(II-O),



(II-P), or

(II-Q),

wherein y and z are each independently an integer from 2 to 12,

u is an integer from 0 to 23,

t is an integer from 1 to 12, and

R^6 is hydrogen or hydroxyl,

or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.

~~29. The compound of any one of claims 1 to 25, wherein R^5 is substituted with one or more hydroxyl and one or more oxo.~~

~~30.~~12. The compound of any one of claims 1 to 11 ~~30~~, wherein R^5 is $–CH_2CH_2OH$.

~~31. The compound of any one of claims 1 to 25, wherein R^5 is $(CH_2)_pQ$, $(CH_2)_pCHQR$, CHQR, or $CQ(R)_2$, wherein Q is C_3-C_8 cycloalkyl, C_3-C_8 cycloalkenyl, C_3-C_8 cycloalkynyl, 4- to 8-membered heterocyclyl, C_6-C_{10} aryl, 5- to 10-membered heteroaryl, OR, $O(CH_2)_pN(R)_2$, C(O)OR, OC(O)R, CX_3, CX_2H, CXH_2, CN, $N(R)_2$, $C(O)N(R)_2$, N(R)C(O)R, $N(R)S(O)_2R$, $N(R)C(O)N(R)_2$, $N(R)C(S)N(R)_2$, $N(R)R^{22}$, $O(CH_2)_pOR$, $N(R)C(=NR^{23})N(R)_2$, $N(R)C(=CHR^{23})N(R)_2$, $OC(O)N(R)_2$, N(R)C(O)OR, N(OR)C(O)R, $N(OR)S(O)_2R$, N(OR)C(O)OR, $N(OR)C(O)N(R)_2$, $N(OR)C(S)N(R)_2$, $N(OR)C(=NR^{23})N(R)_2$, $N(OR)C(=CHR^{23})N(R)_2$, $C(=NR^{23})N(R)_2$, $C(=NR^{23})R$, C(O)N(R)OR, or $C(R)N(R)_2C(O)OR$, and each p is independently 1, 2, 3, 4, or 5;~~


~~R^{22} is C_3-C_8 cycloalkyl, C_3-C_8 cycloalkenyl, C_3-C_8 cycloalkynyl, 4- to 8-membered heterocyclyl, C_6-C_{10} aryl, or 5- to 10-membered heteroaryl;~~

~~R^{23} is H, -CN, $-NO_2$, C_1-C_6 alkyl, -OR, $-S(O)_2R$, $-S(O)_2N(R)_2$, C_2-C_6 alkenyl, C_3-C_8 cycloalkyl, C_3-C_8 cycloalkenyl, C_3-C_8 cycloalkynyl, 4- to 8-membered heterocyclyl, C_6-C_{10} aryl, or 5- to 10-membered heteroaryl;~~


~~each R is independently H, C_1-C_3 alkyl, or C_2-C_3 alkenyl; or two R in a $N(R)_2$ moiety together with the nitrogen to which they are attached form a cyclic moiety; and~~

~~each X is independently F, Cl, Br, or I.~~


~~32.~~13. The compound of claim 1, which is a compound of Formula (I-R), (I-R'), (I-R"), (I-S), (I-T), or (I-U):




(I-R),




(I-R'),




(I-R"),



(I-S),



(I-T), or



(I-U),

wherein y and z are each independently an integer from 2 to 12,


s is an integer from 2 to 24,

t is an integer from 1 to 12, and


R^6 is hydrogen or hydroxyl,

or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.


14. The compound of claim 2, which is a compound of Formula (II-R), (II-R'), (II-R"), (II-S), (II-T), or (II-U):




(II-R),




(II-R'),




(II-R"),



(II-S),



(II-T), or



(II-U),

wherein y and z are each independently an integer from 2 to 12,

u is an integer from 0 to 23,

t is an integer from 1 to 12, and

R^6 is hydrogen or hydroxyl,

or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.

15. The compound of any one of claims 2 to ~~34~~14, wherein R^4 is C_1-C_{12} alkyl.

~~33.~~16. The compound of any one of claims 1 to ~~34~~14, wherein R^4 is C_3-C_8 cycloalkyl.

17. The compound of any one of claims 1 to ~~36~~16, wherein R^4 is unsubstituted.

~~34.~~18. The compound of any one of claims 1 to 16, wherein R^4 is substituted with one hydroxyl.

~~35.~~19. The compound of any one of claims 1 to ~~37~~18, wherein R^1 and R^2 are each independently branched C_6-C_{24} alkyl or branched C_6-C_{24} alkenyl, preferably R^1 and R^2 are each independently -R^7-CH(R^8)(R^9), wherein R^7 is C_1-C_5 alkylene, and R^8 and R^9 are independently C_2-C_{10} alkyl or C_2-C_{10} alkenyl.



~~36. The compound of claim 38, wherein R^1 and R^2 are each independently -R^7-CH(R^8)(R^9), wherein R^7 is C_1-C_5 alkylene, and R^8 and R^9 are independently C_2-C_{10} alkyl or C_2-C_{10} alkenyl.~~











~~37.~~20. The compound of any one of claims 1 to ~~39~~1~~19~~, wherein R^a, R^b, R^d, and R^e are each independently H, and/or, wherein R^c and R^f are each independently branched C_6-C_{24} alkyl or branched C_6-C_{24} alkenyl, preferably R^c and R^f are each independently -R^7-CH(R^8)(R^9), wherein R^7 is C_1-C_5 alkylene, and R^8 and R^9 are independently C_2-C_{10} alkyl or C_2-C_{10} alkenyl.









~~38. The compound of any one of claims 1 to 40, wherein R^e and R^f are each independently branched C_6-C_{24} alkyl or branched C_6-C_{24} alkenyl.~~











~~42. The compound of claim 41, wherein R^e and R^f are each independently -R^7-CH(R^8)(R^9), wherein R^7 is C_1-C_5 alkylene, and R^8 and R^9 are independently C_2-C_{10} alkyl or C_2-C_{10} alkenyl.~~











~~43.~~21. A compound ~~in Table 1,~~which is











	
Compound 1	Compound 2









 Compound 3	 Compound 4
 Compound 5	 Compound 6
 Compound 7	 Compound 8
 Compound 9	 Compound 10
 Compound 11	 Compound 12











 Compound 13	 Compound 14
 Compound 15	 Compound 16
 Compound 17	 Compound 18
 Compound 20	 Compound 21









 Compound 22	 Compound 23
 Compound 24	 Compound 25
 Compound 26	 Compound 27
 Compound 28	 Compound 29
 Compound 30	 Compound 31











 Compound 32	 Compound 33
 Compound 34	 Compound 35
 Compound 36	 Compound 37
 Compound 38	 Compound 39
 Compound 40	 Compound 41











 Compound 42	 Compound 43
 Compound 44	 Compound 45
 Compound 46	 Compound 47
 Compound 48	 Compound 49
 Compound 50	 Compound 51











 Compound 52	 Compound 54
 Compound 55	 Compound 56
 Compound 57	 Compound 58
 Compound 59	 Compound 60











	
Compound 61	Compound 62
	
Compound 63	Compound 64
	
Compound 65	Compound 66
	
Compound 67	Compound 68
	
Compound 69	Compound 70











 Compound 71	 Compound 72
 Compound 73	 Compound 74
 Compound 75	 Compound 76
 Compound 77	 Compound 78











 Compound 79	 Compound 80
 Compound 81	 Compound 82
 Compound 83	 Compound 84
 Compound 85	 Compound 86
 Compound 87	 Compound 88











 Compound 89	 Compound 90
 Compound 91	 Compound 92
 Compound 93	 Compound 94
 Compound 95	 Compound 96
 Compound 97	 Compound 98







 Compound 99	 Compound 101
 Compound 102	 Compound 103
 Compound 104	 Compound 105
 Compound 106	 Compound 107
 Compound 108	 Compound 109

 Compound 110	 Compound 111
 Compound 112	 Compound 113
 Compound 114	 Compound 115
 Compound 116	 Compound 117
 Compound 118	 Compound 119

 Compound 120	 Compound 121
 Compound 122	 Compound 123
 Compound 124	 Compound 125
 Compound 126	 Compound 127
 Compound 128	 Compound 129

 Compound 130	 Compound 131
 Compound 132	 Compound 133
 Compound 134	 Compound 135
 Compound 136	 Compound 137
 Compound 138	 Compound 139

 Compound 140	 Compound 141
 Compound 142	 Compound 143
 Compound 144	 Compound 145
 Compound 146	 Compound 147
 Compound 148	 Compound 149

	
Compound 150	Compound 151
	
Compound 152	Compound 153
	
Compound 154	Compound 155

or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof.

~~44.~~22. A composition comprising the compound of any one of claims 1 to ~~43~~21, and a therapeutic or prophylactic agent.

~~45~~23. The composition of claim ~~44~~22, further comprising one or more ~~structural lipids~~of the following:

(i) further comprising structural lipids, preferably wherein the one or more structural lipids is DSPC,

(ii) further comprising a steroid, preferably wherein the steroid is cholesterol,

(iii) further comprising one or more polymer conjugated lipids, preferably wherein the polymer conjugated lipids is DMG-PEG2000 or DMPE-PEG2000.

24. The composition of claim 23, wherein the therapeutic or prophylactic agent comprises at least one mRNA encoding an antigen or a fragment or epitope thereof, preferably wherein the mRNA is either monocistronic mRNA or multicistronic mRNA, or wherein the mRNA encodes a pathogenic antigen, more preferably wherein the antigen is a tumor associated antigen.

~~46. The composition of claim 45, wherein the one or more structural lipids is DSPC.~~

~~47. The composition of claim 45 or 46, wherein the molar ratio of the compound to the structural lipids ranges from about 2:1 to about 8:1.~~

~~48. The composition of any one of claims 44 to 47, further comprising a steroid.~~

~~49. The composition of claim 48, wherein the steroid is cholesterol.~~

~~50. The composition of claim 48 or 49, wherein the molar ratio of the compound to the steroid ranges from about 5:1 to about 1:1.~~

~~51. The composition of any one of claims 44 to 50, wherein the composition further comprises one or more polymer conjugated lipids.~~

~~52. The composition of claim 51, wherein the polymer conjugated lipids is DMG-PEG2000 or DMPE-PEG2000.~~

~~53. The composition of claim 51 or 52, wherein the molar ratio of the compound to the polymer conjugated lipids ranges from about 100:1 to about 20:1.~~

~~54. The composition of any one of claims 44 to 53, wherein the therapeutic or prophylactic agent comprises at least one mRNA encoding an antigen or a fragment or epitope thereof.~~

~~55. The composition of claim 54, wherein the mRNA is monocistronic mRNA.~~

~~56. The composition of claim 54, wherein the mRNA is multicistronic mRNA.~~

~~57. The composition of any one of claims 54 to 56, wherein the antigen is a pathogenic antigen.~~

~~58. The composition of any one of claims 54to 56, wherein the antigen is a tumor associated antigen.~~

~~59~~25. The composition of ~~any one of~~ claim~~s~~ 23 or 24 ~~54 to 58~~, wherein the mRNA comprises one or more functional nucleotide analog, preferably wherein the functional nucleotide analog is one or more selected from selected from pseudouridine, 1-methyl-pseudouridine and 5-methylcytosine.

~~60. The composition of claim 59, wherein the functional nucleotide analog is one or more selected from pseudouridine, 1-methyl-pseudouridine and 5-methylcytosine.~~

~~61~~26. The composition of any one of claims ~~44~~ 22 to ~~60~~25, wherein the composition is a nanoparticle.

~~62~~27. A lipid nanoparticle comprising the compound of any one of claims 1 to ~~43021~~, or the composition of any one of claims ~~44~~ 22 to ~~60~~25.

~~63~~28. A pharmaceutical composition comprising the compound of any one of claims 1 to ~~43~~21, the composition of any one of claims ~~44~~ 22 to ~~60~~25, or the lipid nanoparticle of claim ~~62~~27, and a pharmaceutically acceptable excipient or diluent.